Data were provided by 131 clinics, and 56% of cases were managed in clinics in the London regions in 2003. Three clinics (2%) do not routinely screen new patients for syphilis, and 28 clinics (21%) do not routinely screen 'rebook' patients who have had a new partner. More than 80% of clinics routinely conduct cardiovascular and neurological examinations, although chest radiography is only performed by 50% of clinics and lumbar puncture by 13%. Only 19 (14%) clinics indicated not routinely using the recommended procaine penicillin G (PPG) regimen or one-or two-dose benzathine penicillin G (BPG) regimens for early syphilis, with 57% providing two doses of BPG 2.4 g, 40% providing PPG 750 mg for 10 days, and 15% providing one dose of BPG 2.4 g. Only seven clinics (5%) indicated that they provided treatment for early syphilis with PPG that is inferior to that recommended in the national guidelines. Only 18 clinics specified using the recommended dose and duration (or in excess of this) of PPG for neurosyphilis for cases with HIV infection. Provision for management of severe penicillin reaction is good, although few patients are desensitized. All clinics report that contact tracing for early syphilis is provided, and is mainly the responsibility of health advisers. Compared with auditing outcomes, audit of management policies overestimated performance in contact tracing and provision of dark ground microscopy.
Introduction
This paper accompanies the two papers that reported on case-note auditing in the UK National Audit of Early Syphilis Management, carried out in 2004 by the National Audit Group in response to increasing numbers of cases of infectious syphilis in the UK. 1, 2 
Methods
The Audit methodology and organization are described in the report on diagnosis and treatment. 1 This part of the Audit describes national averages and regional ranges for measurements of various aspects of clinical management in 2003. The results in this paper are derived from questionnaires sent to the leading clinicians in all genitourinary medicine clinics in the UK. The Questionnaire on Screening for and Management of Early Syphilis is available on the BASHH Website ([www.bashh. org/committees/nag/index.htm]).
Results

Type of clinic and caseload
One hundred and thirty one clinics contributed data, comprising 91 clinics from outside of the London regions and 40 within the London regions. The following types of clinic were recorded: district general hospitals (DGH) (75 clinics, 58%), teaching hospitals (35 clinics, 27%), primary care trust (PCT)/community clinic (15 clinics, 11%), community clinic within an acute trust Medicine & Elderly organization (one clinic), DGH/teaching hospital (one clinic), teaching hospital clinic run in a health centre (one clinic), PCT-managed clinic in a hospital (one clinic), service made up of four PCT clinics and one DGH clinic (one clinic), and not answered (one clinic). Numbers of both early syphilis diagnoses and annual attendances (new plus rebooked) in 2003 were returned for 109 clinics. The median percentage of annual attendances of early syphilis diagnoses for these clinics was: London clinics: 0.09% (clinic range 0.01-0.95%), clinics outside London: 0.09% (clinic range 0.01-1.38%), and overall: 0.09% (clinic range 0.01-1.38). A total of 1527 cases of early syphilis were reported by participating clinics. Management took place in the following types of clinic: teaching hospitals 992 (65%) cases, DGH 400 (26%) cases, PCT 108 (7%) cases, other types of service 18 (1%) cases, and not answered nine (0.6%) cases. Overall, 862 (56%) cases were managed in clinics in the London regions. There were 65 cases of pregnant women with early syphilis and no cases of congenital syphilis.
Use of tests for screening and investigation
Clinics reported screening the following specified patient groups for syphilis in 2003: all new patients, 128 (98%, regional range 80-100%); all 'rebook' patients, 82 (63%, range 0-90%); 'rebook' patients with a new sexual partner since a previous test, 103 (79%, range 0-100%) and pregnant women, 96 (73%, range 0-100%). Table 1 shows the tests used to routinely screen for and investigate early syphilis in 2003. In addition, 16 clinics specified screening routinely for syphilis in patients with HIV infection.
Examinations routinely performed
The following examinations (specified in the audit questionnaire) were reported by clinics as routinely performed in investigating suspected syphilis infection: cardiovascular system examination, 108 (82%, range 50-100%); neurological examination, 107 (82%, range 50-100%); chest radiograph, 66 (50%, range 0-85%); ophthalmic assessment, 44 (34%, range 0-67%); electrocardiogram, 34 (26%, range 0-50%) and lumbar puncture, 17 (13%, range 0-50%). Twenty six comments were returned. Replies from 16 clinics stated that these examinations were necessary, only in latent or late syphilis, or if clinically indicated. Additionally, the following comments about examinations performed were recorded: 'depends on the stage of infection' (two clinics); 'only in secondary, early latent and late syphilis' (one clinic); 'chest radiograph only done for patients older than 35 years' (one clinic) and 'only if clinically indicated' (one clinic). The remaining comments reported on additional examinations performed are as follows: abdominal and eye examination; echocardiogram and ear, nose and throat examination and lumbar puncture if appropriate; genital and skin examination; genital and general examination and oral, rectal and skin examination (one clinic each).
Treatments routinely used to treat early syphilis Table 2 shows the routine use, as reported by clinics, of parenteral penicillin treatments recommended in the UK national guidelines. 3 The recommended treatments for early syphilis with procaine penicillin G (PPG) and/or one-or twodose benzathine penicillin G (BPG) were used in 112 (85%) clinics (with 25 clinics recording use of both the recommended regimen of PPG and twodose BPG, two clinics the recommended regimen of PPG and one-dose BPG, and two all three recommended regimens). Nineteen (14%) clinics indicated not using any of the recommended PPG or BPG regimens. Of these, four clinics, in four regions, specified using 600,000 international units (IU) of PPG (two clinics for 10 days and two clinics for 14 days), five clinics treated early syphilis with 750 mg of PPG for 14 days (four of which also used doxycycline regimens), one clinic specified using 1.2 mega units of PPG for 10 days, one clinic specified using doxycycline 100 mg twice daily (b.d.) for 14 days only, and one clinic 'treatment according to national guidelines', and the remaining seven clinics provided no further information. Five of the clinics that used recommended PPG and/or BPG treatments also specified using nonrecommended treatments: three clinics reported using 600,000 IU of PPG, one clinic for 14 days and the other two clinics for 10 days, and two clinics also specified treating early syphilis with 750 mg of PPG for 14 days.
Nationally, 26 (20%) clinics routinely used doxycycline to treat early syphilis, of which 14 (54%) used the recommended regimen of 100 mg b.d. for 14 days. The other 12 clinics used the Three clinics specified using PPG for epidemiological treatment with less than 750 mg of PPG: 600,000 IU for 10 days (two clinics) and 600,000 IU for 14 days (one clinic). Four clinics used 750 mg of PPG for 14 days for epidemiological treatment. Thirteen clinics specified use of doxycycline regimens for epidemiological treatment (including five clinics that also used PPG regimens): 100 mg b.d. for 14 days (six clinics); 200 mg b.d. for 14 days (one clinic); 200 mg b.d. for 28 days (two clinics); 200 mg dosing not specified for 28 days (one clinic); 300 mg o.d. for 21 days (two clinics) and not specified (one clinic). Six clinics specified using azithromycin, one clinic used either doxycycline or azithromycin, and one clinic specified use of national guidelines for epidemiological treatment. Two clinics specified that epidemiological treatment was not routinely offered.
In cases with HIV infection, treatments recommended for early syphilis (750 mg of PPG for 10 days and/or one-or two-dose BPG) were used in 51 (39%) clinics (with six clinics recording use of both the recommended regimen of PPG and twodose BPG). A further 51 (39%) clinics indicated using a PPG or BPG regimen in HIV infection other than that recommended for early syphilis. Of these, 38 (75%) clinics specified PPG regimens in excess of 750 mg o.d. and/or for longer than 10 days (and not represented in for 17 days (one clinic); Jenacillin (preparation not specified) 8 mL for 17 days (one clinic); Tubex (preparation not specified) 3 mL for 17 days (one clinic) and Jenacillin A 6.5 mL for 21 days (one clinic). Twelve (32%) of these clinics specified use of probenecid with PPG treatments (there was no other use of probenecid reported apart from this use for patients with HIV infection).
Thirteen (25%) clinics used three-dose BPG as the only penicillin treatment in cases with HIV infection.
Of the remaining 29 (22%) clinics, one clinic each recorded treatment as for late latent syphilis, PPG treatment with 600,000 IU o.d. for 10 days, non-specified use of PPG, doxycycline 400 mg (dosing not specified) for 14 days, treatment according to national guidelines and a non-specified treatment for 14 days, and 23 clinics did not report a treatment for early syphilis cases with HIV infection.
Six clinics (two of which also used a recommended PPG or BPG treatment for early syphilis) specified use of doxycycline for treatment of patients with HIV infection: 100 mg (dosing not specified) for 21 days (one clinic); 200 mg (dosing not specified) for 14 days (one clinic); 200 mg b.d. for 28 days (two clinics); 200 mg b.d. for 20 days (one clinic) and 400 mg (dosing not specified) for 28 days (one clinic). Additionally, one clinic each Figures are presented as number of clinics using a particular treatment (national percentages, regional ranges as percentages) Ã More than one choice of treatment was used w Duration of 17 days specified for three cases z Treatments for congenital syphilis y Duration of 14 days specified for one case IM=intra-muscular; NA=not applicable specified use of intravenous ceftriaxone, PPG 600,000 IU o.d. for 10 days, and 750 mg o.d. for 21 days (all of which also specified a use of a recommended regimen for early syphilis) to treat early syphilis in cases with HIV infection.
Contact tracing
All clinics reported providing contact tracing. Contact tracing was recorded as the responsibility of health advisers for 121 (92%, range 70-100%) clinics, doctors 38 (29%, range 0-100%) and nurses 16 (12%, 0-50%). One clinic recorded that a health practitioner had responsibility for contact tracing (although doctor and nurse responsibility was also recorded for this clinic), and another clinic reported that contact tracing was the responsibility of a combined nurse/health adviser.
Allergic reaction management
Only 27 clinics (21%, range 2-50%) reported 48 patients with early syphilis as having penicillin allergy. Only two patients, both treated at the same clinic, were de-sensitized to penicillin. Ten clinics reported not having facilities for managing a patient who develops a severe reaction to treatment (anaphylaxis, procaine reaction); nine of these clinics stated having alternative provision for management of severe reaction to treatment (acute hospital services and crash teams).
Discussion
The preponderance of management of early syphilis in teaching hospitals (about two-thirds of cases were managed in teaching hospitals, which made up about one quarter of the total number of clinics) reflects their usually larger patient workload and their frequent location in areas of particular need, and highlights the importance of clinics sharing information about practice in regional audit groups. Although physical examination of the cardiovascular and neurological systems is reported as routinely performed in the investigation of suspected early syphilis by over 80% of clinics, chest radiography is less often performed and lumbar puncture is infrequently carried out. A significant minority of clinics indicated that these examinations and tests are not necessary in early syphilis.
There is agreement with the stated use of tests for screening for and investigation of early syphilis between this part of the Audit and the Case-Notes Audit with regard to the following: use of an enzyme immunoassay test by most clinics; more frequent use of the Venereal Diseases Research Laboratory test than of the rapid plasma reagin test; more frequent use of the treponemal pallidum particle agglutination assay test than of the Treponema pallidum haemagglutination assay test and little use of polymerase chain reaction and direct fluorescent antibody tests.
Only seven clinics reported using a regimen inferior to that recommended in the national guidelines 3 and a further seven clinics provided no information about treatment of early syphilis. BPG 2.4 g was the most commonly used treatment, two doses being more commonly used than one. Relatively few clinics reported using PPG treatments in excess of those recommended by the national guidelines for cases without HIV infection, although this was much more commonly done for cases with HIV infection (29% of clinics). Nearly all clinics that used doxycycline treatments to treat early syphilis used also PPG and/or BPG regimens. About half of doxycycline treatments were with the regimen recommended in the national guidelines. 3 The national guidelines state that treatment of cases with early syphilis and HIV infection is 'as for neurosyphilis'. However, only 18 clinics specified using the recommended dose and duration (or in excess of this) of PPG for neurosyphilis for cases with HIV infection (and only 10 of these specified using probenecid), and only two clinics specified the recommended doxycycline regimen for neurosyphilis.
The results from this part of the Audit serve to illustrate the disparity in results that may be found when both management policies and outcome are audited. The reported use of dark ground microscopy (DGM) by 74% of clinics does not accord with the actual provision of DGM reported in the Case-Notes Audit (32 of 107 (30%) clinics). 2 This may be explained by the finding of the British Co-operative Clinical Group survey conducted in 2002, which identified that 35% of clinics were not confident of their ability to obtain an adequate specimen for DGM, and 64% were not confident of their expertise to detect treponemes on DGM. 4 The Bacterial Special Interest Group of British Association for Sexual Health and HIV (BASHH) has subsequently developed and delivered a training course on DGM.
Although all clinics claimed to perform contact tracing, in the Case-Notes Audit, approximately 15% of cases were not provided with contact tracing, and 100% contact tracing was not recorded for any region. 2 Likewise, disparity between policy and outcome measures has been reported in the context of another area of sexually transmitted infection management -namely hepatitis B/C infection in patients with HIV infection. 5 Facilities for managing severe reactions to penicillin treatments appear to be good. However, few patients seem to undergo penicillin desensitization, despite the fact that this has been shown to be an effective management strategy, including during pregnancy, 6 and is suggested as a therapeutic option in the national guidelines. 3 
